NEU 0.49% $20.42 neuren pharmaceuticals limited

Ann: Investor Presentation, 14 March 2023, page-63

  1. 727 Posts.
    lightbulb Created with Sketch. 167
    interesting legalities. Given that 2591 has already been granted FDA orphan designation for PW, wouldn't that null the anti competetive clauses for that condition? suppose acadia came out and said we are targeting PW with trof, and 6 months later neuren lodged a ophan application for 2591, then sure - but the other way around?

    tried to read the licencing agreement but ran out of coffee
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.